Is CORCEPT THERAPEUTICS INC (CORT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 10.3% / 30% | 1.7% / 30% | 2.85% / 5% | ✓ HALAL |
| DJIM | 0.2% / 33% | 10.3% / 33% | 1.7% / 33% | 2.85% / 5% | ✓ HALAL |
| MSCI | 0.7% / 33% | 44.5% / 33% | 7.1% / 33% | 2.85% / 5% | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 10.3% / 33% | 1.7% / 33% | 2.85% / 5% | ✓ HALAL |
| FTSE | 0.7% / 33% | 44.5% / 33% | 7.1% / 50% | 2.85% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 98.3% | |
| Operating Margin | 2.2% | |
| Net Margin | 13.1% | |
| Return on Equity (ROE) | 15.0% | |
| Return on Assets (ROA) | 3.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $142M |
| Free Cash Flow | $142M |
| Total Debt | $6M |
| Debt-to-Equity | 0.9 |
| Current Ratio | 2.9 |
| Total Assets | $837M |
Price & Trading
| Last Close | $38.53 |
| 50-Day MA | $37.44 |
| 200-Day MA | $64.02 |
| Avg Volume | 2.3M |
| Beta | 0.3 |
|
52-Week Range
$28.66
| |
About CORCEPT THERAPEUTICS INC (CORT)
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Purification Calculator
As a halal stock with 2.85% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CORCEPT THERAPEUTICS INC (CORT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CORCEPT THERAPEUTICS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CORCEPT THERAPEUTICS INC's debt ratio?
CORCEPT THERAPEUTICS INC's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
Does CORCEPT THERAPEUTICS INC require dividend purification?
Yes, CORCEPT THERAPEUTICS INC has an impermissible income ratio of 2.85%, which means 2.85% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are CORCEPT THERAPEUTICS INC's key financial metrics?
CORCEPT THERAPEUTICS INC has a market capitalization of $4.0B, trailing P/E ratio of 45.9, and revenue of $761M. The company maintains a gross margin of 98.3% and a net margin of 13.1%. Return on equity stands at 15.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.